Cumulative evidence for relationships between multiple variants of HNF1B and the risk of prostate and endometrial cancers

BACKGROUND: To provide a synopsis of the current understanding of the association between variants of HNF1B and cancer susceptibility, we conducted a comprehensive research synopsis and meta-analysis to evaluate associations between HNF1B variants and prostate and endometrial cancers. RESULTS: Eighteen studies totaling 34,937 patients and 55,969 controls were eligible for this meta-analysis. Four variants showed a significant association with the risk of individual cancer. Strong significant associations were found between rs4430796 A and the risk of both prostate cancer (OR = 1.247, p = 2.21 × 10(− 77)) and endometrial cancer (OR = 1.217, p = 8.98 × 10(− 16)); the AA, AG genotypes also showed strong significant associations with the risk of prostate cancer (OR1 = 1.517, p = 4.46 × 10(− 22); OR2 = 1.180, p = 0.002). There was a strong significant association between rs7501939 G and the risk of prostate cancer (OR = 1.201, p = 9.31 × 10(− 31)). Strong significant association was found between rs11649743 G (OR = 1.138, p = 1.08 × 10(− 12)), rs3760511 C (OR = 1.214, p = 1.57 × 10(− 19)) and the prostate cancer risk;the GG, AG genotypes of rs11649743 also showed strong significant associations with the risk of prostate cancer (OR1 = 1.496, p = 3.32 × 10(− 6); OR2 = 1.276, p = 7.82 × 10(− 6)). All the cumulative epidemiological evidence of associations was graded as strong. CONCLUSIONS: Our study summarizes the evidence and helps to reveal that common variants of HNF1B are associated with risk of prostate and endometrial cancer.